Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Bladder cancer cell‑secreted exosomal miR‑21 activates the PI3K/AKT pathway in macrophages to promote cancer progression.
|
31814034 |
2020 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Frequent mutations and gene expression alterations in the PI3K/AKT and mitogen-activated protein kinase-ERK pathways lead to deregulated cell growth and the acquisition of invasive properties, which facilitates tumour progression and confers resistance to chemotherapy.
|
31829429 |
2020 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This finding provides a link between SSEA3/SSEA4/Globo-H and the FAK/CAV1/AKT/RIP complex in tumor progression and apoptosis and suggests a direction for the treatment of breast cancer, as demonstrated by the combined use of antibodies against Globo-H and SSEA4.
|
30808745 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
UNBS5162 and amonafide inhibits tumor progression in human melanoma by the AKT/mTOR pathway.
|
30962721 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Taking account of conflicting findings among the studies, the majority of the studies reported a tumor initiating role of AKT1, whereas AKT2 is mainly responsible for tumor progression and metastasis.
|
31752925 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Paip1 predicts poor prognosis and promotes tumor progression through AKT/GSK-3β pathway in lung adenocarcinoma.
|
30496797 |
2019 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Here we show that three LPA receptors are involved in tumor progression by activation of both the AKT and ERK signaling pathways.
|
31636669 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
However, the potential mechanisms of AKT in the tumor progression of endometrial cancer remain unclear.
|
31781484 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The cytoplasmic domain is critical for that activation and involves focal adhesion kinase (FAK), extracellular regulated kinase (ERK1/2), and protein kinase B (AKT/PKB) signaling, further contributing to cancer progression and mediating chemoresistance against first-line therapies.
|
30635388 |
2019 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling.
|
30688659 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Mechanistically, high levels of TRIM44 increased the levels of p-AKT (T308) and p-mTOR (S2448), and a specific AKT inhibitor inhibited TRIM44-induced tumor progression.
|
30922374 |
2019 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Human osteosarcomas U-2 OS or MG-63 were treated with regorafenib, miltefosine (protein kinase B (AKT) inhibitor), or PD98059 (mitogen-activated protein/extracellular signal-regulated kinase (MEK) pathway inhibitor) for 24 or 48 h. Cell viability, apoptotic signaling transduction, tumor invasion, expression of tumor progression-associated proteins and tumor growth after regorafenib treatment were assayed by MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, flow cytometry, transwell assay, Western blotting assay and in vivo animal experiment, respectively.
|
31238539 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo.
|
31163381 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We established multiple oligodendroglioma xenografts to determine if the PI3K/AKT/mTOR signaling pathway drives tumor progression.
|
30975663 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Upregulation of OTUD7B (Cezanne) Promotes Tumor Progression via AKT/VEGF Pathway in Lung Squamous Carcinoma and Adenocarcinoma.
|
31572671 |
2019 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Testis-specific protein, Y-linked 1 activates PI3K/AKT and RAS signaling pathways through suppressing IGFBP3 expression during tumor progression.
|
30815935 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Both PECAM1 and ADCY7 promoted tumor progression through the AKT pathway, showing the same molecular mechanism as CD300A.
|
29938007 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma.
|
29541403 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Genetic alterations driving aberrant activation of the survival kinase Protein Kinase B (Akt) are observed with high frequency during malignant transformation and cancer progression.
|
29562639 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Since AKT and Stat3 play an important role in EMT and tumor progression, we examined whether there is a correlation between NFIB and AKT/Stat3 signaling pathways in GC.
|
30015981 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
However, it has been found that AKT1 and AKT3 isoforms have a main role in tumor progression and metastasis; thus, the identification of AKT isoforms specific inhibitors seems to be a challenge.
|
28150530 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We showed that CXCL8 secreted by tumor cells at the invasion front were able to promote migration through angiogenesis by upregulating VEGFA and invasion via the AKT/GSK3β/β-catenin/MMP7 pathway by upregulating BCL-2 confirming the key role of CXCL8 during tumor progression.
|
29679563 |
2018 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Estrogen activated the AKT pathway in BRCA1-deficient tumor cells independent of ER, and pharmaceutical inhibition of AKT activity suppressed EMT and cell proliferation preventing BRCA1 deficient tumor progression.
|
29996906 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
TIS21<sup>/BTG2</sup> significantly lost in the infiltrating ductal carcinoma, but it can inhibit cancer growth via the TIS21<sup>/BTG2</sup>-tsc1/2-mTORc1-p70S6K axis and downregulate cancer progression via the TIS21<sup>/BTG2</sup>-mTORc2-AKT1-NFAT1-PHLPP2 pathway.
|
29808317 |
2018 |
Tumor Progression
|
0.100 |
PosttranslationalModification
|
phenotype |
BEFREE |
These results prompted us to investigate the factors affecting the tumorigenicity of <i>MAEL</i> Further experimentation demonstrated that <i>MAEL</i> enhanced the expression of phosphorylated Akt1, with subsequent phosphorylation of nuclear factor kappa B (NF-κB) subunit RelA in tumor cells, and chemoattracted myeloid-derived suppressor cells (MDSCs) by upregulating interleukin-8 (IL8) to accelerate tumor progression in the tumor microenvironment.
|
30082413 |
2018 |